Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00243204
Status:
TERMINATED
Last Update Posted:
2007-06-08
First Post:
2005-10-19
Brief Title:
Study of Talabostat Docetaxel Versus Docetaxel in Stage IIIBIV Non-Small Cell Lung Cancer NSCLC After Failure of Platinum-Based Chemotherapy
Sponsor:
Point Therapeutics
Organization:
Point Therapeutics
Organization Data
Organization:
Point Therapeutics
Class:
INDUSTRY
Study ID:
PTH-304
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Point Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None